Cystic fibrosis (CF) is the most common inherited life-limiting disorder among Caucasians. The implementation of CF newborn screening has enabled early diagnosis and prompt treatment onset. However, several factors may affect circulating levels of immunoreactive trypsinogen leading to a normal CF newborn screen. This case aims to highlight the importance of taking clinical manifestations as a strong factor for the diagnosis of CF even in the presence of a negative newborn screen. This may allow early referral to a specialized CF center where the onset of appropriate treatment can be implemented, thereby positively impacting the course of the disease.
Introduction
Cystic fibrosis (CF) is an autosomal recessive inherited disease and the most common life-limiting disorder among Caucasians. It affects nearly 30,000 children in the United States and almost 70,000 individuals worldwide [1, 2] . CF is characterized by mutations in the CF transmembrane regulator (CFTR) gene, which encodes a membrane chloride channel, causing dysregulation of ion and water exchange. This results in decrease of airway surface liquid and an increase in abnormally thick mucus, which is consequential in a wide range of clinical manifestations including sinopulmonary, gastrointestinal, and reproductive [2, 3] .
Alongside with advances in CF therapies, an improvement in survival of patients affected by CF has evolved.
Currently, the median survival outcome approaches the age of 40 years old. In addition, new mutation-specific medications directed at the defective CFTR protein have generated an important shift in the current management of 
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CF as well as its morbidity and mortality rates [2] . At present, newborn screening is frequently implemented for CF diagnosis, which allow for an early identification of the disease even before the onset of symptoms [4] . In this report, we present the case of a 3-year-old patient whose newborn screening failed to diagnose CF, resulting in the delay of referral to a CF-specialized center for appropriate treatment initiation. 
Case Report

Discussion
CF-related lung disease often has an early onset even before the appearance of clinical manifestations. It is characterized by impaired mucociliary clearance and chronic neutrophilic inflammation leading to a vicious cycle of obstruction, inflammation, and infection that consequently results in the development of bronchiectasis, respiratory failure and death [2, [4] [5] [6] . Meconium ileus, bleeding due to vitamin K deficiency, and prolonged jaundice may be present during the neonatal period. During infancy, hyponatremic and hypochloremic alkalotic dehydration can occur in some cases as a result of salt loss through sweat [7] . Many patients with CF have pancreatic exocrine insufficiency, resulting in malabsorption of fat, protein and fat-soluble vitamins. In addition, they may experience constipation, distal intestinal obstruction syndrome, rectal prolapse, and hepatobiliary disease and gallstones [7, 8] . Rep 2019; 3 (6) : 611-614 DOI: 10.26502/acmcr.96550142
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The postnatal diagnosis of CF must be based on the presence of one or more characteristic clinical features, the history of a sibling with CF, or a positive newborn screening test as well as laboratory evidence of an abnormality in the CFTR gene, such as biological evidence of channel dysfunction (sweat test) or identification of a CF diseasecausing mutation on each chromosome [3] . The measurement of immunoreactive trypsinogen is used as the primary screening tool for CF. After the identification of an abnormal IRT, a DNA testing (IRT/DNA) or a repeat IRT measurement, obtaining a second blood sample after 2 weeks (IRT/IRT) should take place; nonetheless, several factors have shown to affect the circulating levels of IRT [3, 5] . A sweat chloride concentration > 60 mmol/L is considered abnormal [1] . [3] .
Early onset of treatment in CF patients should be implemented as evidence has shown the presence of structural and functional abnormalities even before symptoms appear [4] . Current treatments for CF consist of a multidisciplinary approach-integration of airway clearance techniques, physical activity and nutritional support to help maintain pulmonary health, use of drug therapy including mucolytics (dornase alpha), hydration therapy, antibiotics, CFTR modulator therapy, and psychosocial assistance. Transplantation is an established therapy for end-stage lung and liver disease in CF patients [9] .
Conclusion
Our case has aimed to highlight the importance of taking clinical manifestations as a strong factor for the diagnosis of CF even in the presence of a negative initial test. This will be of great assistance as the patients can be immediately referred to a specialized CF center, whereby the onset of appropriate treatment can be done that would positively impact the course of the disease.
